MRK - Merck & Co., Inc.
NEXT EARNINGS:
Apr 30, 2026
EPS Est: $-1.46
|
Rev Est: $15.9B
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$123.92
DETAILS
HIGH:
$150.00
LOW:
$90.00
MEDIAN:
$130.00
CONSENSUS:
$123.92
DOWNSIDE:
0.01%
Market Cap:
309.55B
Volume:
6,609,393
Avg Volume:
13,868,360
52 Week Range:
73.31-124.84
Sector:
Healthcare
Industry:
Drug Manufacturers - General
Beta:
0.30
Last Dividend:
$3.28
Exchange:
NYSE
Country:
US
Employees:
73,000
IPO Date:
1978-01-13
EPS (TTM):
7.28
P/E Ratio:
14.46
Revenue (TTM):
65.01B
Total Assets:
N/A
Total Debt:
N/A
Cash & Equiv:
N/A
Rev Growth (5Y):
9.4%
EPS Growth (5Y):
21.1%
FCF Growth (5Y):
12.7%
ROCE:
N/A
Debt/Equity:
N/A
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-03 | $2.04 | $2.01 | +1.5% | $16.4B | $16.2B | +1.2% |
| 2025-10-30 | $2.58 | $2.36 | +9.3% | $17.3B | $17.0B | +1.8% |
| 2025-07-29 | $2.13 | $2.03 | +4.9% | $15.8B | $15.9B | -0.4% |
| 2025-04-24 | $2.22 | $2.13 | +4.2% | $15.5B | $15.3B | +1.2% |
| 2025-02-04 | $1.72 | $1.85 | -7.0% | $15.6B | $15.5B | +0.9% |
| 2024-10-31 | $1.57 | $1.50 | +4.7% | $16.7B | $16.5B | +1.1% |
| 2024-07-30 | $2.28 | $2.15 | +6.0% | $16.1B | $15.9B | +1.5% |
| 2024-04-25 | $2.07 | $1.88 | +10.1% | $15.8B | $15.2B | +3.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.01B | 64.17B | 60.12B | 59.28B | 48.70B | 41.52B | 39.12B | 42.29B | 40.12B | 39.81B | 39.50B | 42.24B |
| Net Income | 18.25B | 17.12B | 365.00M | 14.52B | 13.05B | 7.07B | 9.84B | 6.22B | 2.39B | 3.92B | 4.44B | 11.92B |
| EPS | 7.28 | 6.76 | 0.14 | 5.73 | 5.16 | 2.79 | 3.84 | 2.40 | 0.95 | 2.07 | 1.60 | 4.20 |
| Total Assets | 0 | 117.11B | 106.67B | 109.16B | 105.69B | 91.59B | 84.40B | 82.64B | 87.87B | 95.38B | 101.68B | 98.17B |
| Total Debt | 0 | 38.27B | 36.27B | 31.98B | 34.63B | 33.42B | 27.35B | 25.11B | 24.41B | 24.84B | 26.41B | 21.40B |
| Cash & Equivalents | 0 | 13.24B | 6.84B | 12.69B | 8.10B | 8.05B | 9.68B | 7.96B | 6.09B | 6.51B | 8.52B | 7.44B |
| Operating Cash Flow | 0 | 21.47B | 13.01B | 19.09B | 14.11B | 10.25B | 13.44B | 10.92B | 6.45B | 10.38B | 12.42B | 7.86B |
| Free Cash Flow | 0 | 18.10B | 9.14B | 14.71B | 9.66B | 5.57B | 9.97B | 8.31B | 4.56B | 8.76B | 11.14B | 5.54B |
| FCF per Share | N/A | 7.15 | 3.51 | 5.81 | 3.82 | 2.20 | 3.89 | 3.20 | 1.69 | 3.19 | 4.00 | 1.95 |
| Book Value | 51.91B | 46.31B | 37.58B | 45.99B | 38.18B | 25.32B | 25.91B | 26.70B | 34.34B | 40.09B | 44.68B | 48.65B |
| Cash & ST Investments | 18.21B | 13.69B | 7.09B | 13.19B | 8.10B | 8.05B | 10.45B | 8.86B | 8.50B | 14.34B | 13.43B | 15.72B |
| ROC Equity | 0.35 | 0.37 | 0.01 | 0.32 | 0.34 | 0.28 | 0.38 | 0.23 | 0.07 | 0.10 | 0.10 | 0.25 |